Abbott (NYSE:ABT)
(ABT shares +0.2% since Feb. 19)
“We can see a recovery into Q3 and into Q4, especially for these more elective procedures. There are some that, yeah, you can push out, but they are important. They are lifesaving. They are solving some significant problems, whether it’s a stent, a pacemaker, repairing a mitral valve. … I don’t believe that they’re going to come back at the same speed that they came down, but like I said, these are important procedures and I do see them coming back. … Clearly, it’s quite possible that other industries might take longer to recover, but I think for healthcare, the data — our modeling here suggest the kind of recovery that I’ve just described.”
— Robert B. Ford, CEO of Abbott